Current Time 0:00
/
Duration Time 0:00
Progress: NaN%
Playback Rate
1.00x

Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling

Research Square

Research Square

  • First Author :
    Tony Yaksh
  • Co-authors :
    Kelly Eddinger;Shinichi Kokubu;Zhenping Wang;Anna DiNardo;Roshni Ramachandran;Yuelian Zhu;Yajun He;Fieke Weren;Daphne Quang;Shelle Malkmus;Katherine Lansu;Wesley Kroeze;Brian Eliceiri;Joanne Steinauer;Peter Schiller;Peter Gmeiner;Linda Page;Keith Hildebrand
  • Journal Name :
    OVID
  • Read Full text :
  • DOI :
    10.1097/ALN.0000000000002730

Share This Video

Abstract

What We Already Know about This Topic The formation of intrathecal masses complicates the use of intrathecal opioid therapy for chronic pain The degranulation of mast cells has been linked to intrathecal mass formation What This Article Tells Us That Is New Using a guinea pig model, masses formed around intrathecal catheters when morphine was infused, and this mass formation was not prevented by opioid receptor blockade Non-opioid receptor mediated stimulation of Mas-related G protein-coupled receptor appeared to be mechanism responsible for mast cell degranulation, fibroblast proliferation and ultimately mass formation Agents not activating Mas-related genes at analgesic doses did not produce masses Background: As the meningeally derived, fibroblast-rich, mass-produced by intrathecal morphine infusion is not produced by all opiates, but reduced by mast cell stabilizers, the authors hypothesized a role for meningeal mast cell/fibroblast activation. Using the guinea pig, the authors asked: (1) Are intrathecal morphine masses blocked by opiate antagonism?; (2) Do opioid agonists not producing mast cell degranulation or fibroblast activation produce masses?; and (3) Do masses covary with Mas-related G protein-coupled receptor signaling thought to mediate mast cell degranulation? Methods: In adult male guinea pigs (N = 66), lumbar intrathecal catheters connected to osmotic minipumps (14 days; 0.5 µl/h) were placed to deliver saline or equianalgesic concentrations of morphine sulfate (33 nmol/h), 2’,6’-dimethyl tyrosine-(Tyr-D-Arg-Phe-Lys-NH2) (abbreviated as DMT-DALDA; 10 pmol/h; μ agonist) or PZM21 (27 nmol/h; biased μ agonist). A second pump delivered subcutaneous naltrexone (25 µg/h) in some animals. After 14 to 16 days, animals were anesthetized and perfusion-fixed. Drug effects on degranulation of human cultured mast cells, mouse embryonic fibroblast activation/migration/collagen formation, and Mas-related G protein-coupled receptor activation (PRESTO-Tango assays) were determined. Results: Intrathecal infusion of morphine, DMT-DALDA or PZM21, but not saline, comparably increased thermal thresholds for 7 days. Spinal masses proximal to catheter tip, composed of fibroblast/collagen type I (median: interquartile range, 0 to 4 scale), were produced by morphine (2.3: 2.0 to 3.5) and morphine plus naltrexone (2.5: 1.4 to 3.1), but not vehicle (1.2: 1.1 to 1.5), DMT-DALDA (1.0: 0.6 to 1.3), or PZM21 (0.5: 0.4 to 0.8). Morphine in a naloxone-insensitive fashion, but not PZM21 or DMT-DALDA, resulted in mast cell degranulation and fibroblast proliferation/collagen formation. Morphine-induced fibroblast proliferation, as mast cell degranulation, is blocked by cromolyn. Mas-related G protein-coupled receptor activation was produced by morphine and TAN67 (∂-opioid agonist), but not by PZM21, TRV130 (mu biased ligand), or DMT-DALDA. Conclusions: Opiates that activate Mas-related G protein-coupled receptor will degranulate mast cells, activate fibroblasts, and result in intrathecal mass formation. Results suggest a mechanistically rational path forward to safer intrathecal opioid therapeutics.

Ask Questions 0

Please Login or Register to add your question

Recommended Videos

No recommendation found